Papillary Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Papillary Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of Bevacizumab, Erlotinib, and Atezolizumab for advanced renal cell carcinoma. The study i…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study [Phase 2]
Phase 2 trial exploring the addition of radium-223 dichloride to cabozantinib for advanced renal cell carcinoma with bone metastases (RadiCa…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial [Phase 2]
Phase 2 PAPMET2 trial evaluates cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma, includin…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) [Phase 1, Phase 2]
A sponsor-backed Phase 1/2 clinical trial evaluates the combination of palbociclib and sasanlimab for advanced clear cell renal cell carcino…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer [Phase 1]
Phase 1 trial evaluating CBM588 in combination with nivolumab and cabozantinib for advanced or metastatic renal cell carcinoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
A Mayo Clinic-led clinical trial is evaluating whether tumor-derived extracellular vesicles can noninvasively classify different kidney canc…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy [NA]
This is an update on a clinical research study (NCT04623502) investigating kidney and urothelial tumor metabolism in patients undergoing sur…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC [Phase 2]
Phase 2 clinical trial update evaluating cabozantinib in combination with nivolumab and ipilimumab for advanced non-clear cell renal cell ca…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating cabozantinib or sunitinib malate in patients with metastatic variant histology renal cell carcinoma, inclu…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
A Mayo Clinic-led INQUIRE study is identifying novel high-quality methylated DNA markers for renal tumors. The project uses whole-methylome …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
A real-world study in China evaluating the effectiveness of sunitinib or sorafenib for unresectable, locally advanced or metastatic papillar…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 study of nivolumab in combination with cabozantinib in patients with non-clear cell renal cell carcinoma; the trial is currently act…
-
CLINICAL_TRIALS research · 2025-05-08Clinical Trial Update: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC [Phase 3]
Phase 3 trial comparing Savolitinib plus Durvalumab versus Sunitinib and Durvalumab monotherapy in MET-driven papillary renal cell carcinoma…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Study of Kidney Tumors in Younger Patients
The Children's Oncology Group study of kidney tumors in younger patients is currently active but not recruiting. It covers multiple pediatri…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology [Phase 1]
Phase 1 study assessing safety, pharmacokinetics, and preliminary effectiveness of AGS-16C3F as monotherapy in renal cell carcinoma with cle…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: CREATE: Cross-tumoral Phase 2 With Crizotinib [Phase 2]
Phase 2 cross-tumor trial evaluating crizotinib in multiple locally advanced or metastatic cancers; study completed.
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy [Phase 3]
Phase 3 clinical trial evaluating a multi-classifier system to stratify stage III papillary renal cell carcinoma in the adjuvant therapy set…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer [Phase 2]
Phase 2 study of the MET kinase inhibitor INC280 (epernestib) in papillary renal cell cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-09-06Clinical Trial Update: Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating axitinib as first-line treatment for advanced or metastatic papillary renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed [Phase 2]
A Phase 2 trial update reports results from testing cabozantinib, crizotinib, savolitinib, and sunitinib in patients with locally advanced o…
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma [Phase 1, Phase 2]
A Phase 1/2 trial studying vandetanib combined with metformin in patients with hereditary leiomyomatosis-related renal cell carcinoma (HLRCC…
-
CLINICAL_TRIALS trial_result · 2020-07-10Clinical Trial Update: Savolitinib vs. Sunitinib in MET-driven PRCC. [Phase 3]
A Phase 3 trial comparing savolitinib to sunitinib in MET-driven papillary renal cell carcinoma has posted results and is not currently recr…
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer [Phase 2]
Phase 2 trial results for Pazopanib hydrochloride in metastatic or recurrent kidney cancers have been posted after the study completed, incl…
-
CLINICAL_TRIALS trial_result · 2017-12-11Clinical Trial Update: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) [Phase 2]
Phase II clinical trial results update for GSK1363089 (XL880) in patients with papillary renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2017-10-12Clinical Trial Update: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) [Phase 2]
Phase II trial evaluating AZD6094 (HMPL-504) in papillary renal cell carcinoma has completed with results posted in 2017.